top of page
Search

Alzheimer's disease testing innovation

  • demarcolab
  • Jun 30, 2020
  • 1 min read

The IMPACT-AD team's Alzheimer's disease testing innovation for amyloid-beta proteoforms has been published in a leading scientific journal!



The first method to identify both sporadic and autosomal dominant Alzheimer's disease

This is the first method to identify both sporadic AD (by wt-Aβ42 and wt-Aβ40 concentration) and autosomal dominant AD (by identification of pathogenic APP variants) in one anatysis, enabling biomarker testing without a priori knowledge of the genetic makeup of an individual.


Fully-automated & calibrated to the international standard

Development of an automated workflow and selection of appropriate instrumentation enabled deployment of this method for routine patient testing in Canada!


 
 
 

コメント


この投稿へのコメントは利用できなくなりました。詳細はサイト所有者にお問い合わせください。

© 2018 by ML DeMarco

bottom of page